MIT's Gut Protein Discovery May Transform IBD Treatment

A Hidden Guardian in the Gut

Deep within the lining of the gastrointestinal tract, a little-known protein has been quietly performing two critical jobs at once. Researchers at the Massachusetts Institute of Technology have identified intelectin-2, a protein that both reinforces the protective mucus barrier of the intestine and directly attacks harmful bacteria — including some of the most antibiotic-resistant pathogens known to medicine.

The study, published in Nature Communications and led by Amanda Dugan and Deepsing Syangtan under senior author Laura Kiessling, sheds new light on the body's innate immune defenses and could reshape how scientists approach treatment for inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis.

How Intelectin-2 Works

Intelectin-2 is a lectin — a protein that recognizes and binds to specific sugar molecules. The MIT team found that it targets galactose, a sugar present in two very different contexts: the mucin proteins that make up intestinal mucus, and the carbohydrates displayed on the outer surface of many bacterial cells.

This dual binding capacity gives the protein a two-pronged defensive strategy. When intelectin-2 attaches to mucins, it crosslinks them, physically strengthening the mucus layer that serves as the gut's first line of defense. If bacteria manage to breach that barrier, the protein binds to microbial surfaces and inhibits their growth — or kills them outright.

"Intelectin-2 first reinforces the mucus barrier itself, and then if that barrier is breached, it can control the bacteria and restrict their growth," the researchers noted.

Critically, the antimicrobial activity was selective: bacteria bound by intelectin-2 suffered loss of viability, while human cells remained unharmed. The protein was effective against a broad spectrum of pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and Klebsiella pneumoniae — bacteria notorious for resisting standard antibiotics.

Implications for Inflammatory Bowel Disease

The discovery carries significant implications for the more than 10 million people worldwide living with IBD. In these patients, intelectin-2 levels are frequently dysregulated — either abnormally low, which weakens the mucus barrier and leaves the gut vulnerable to microbial invasion, or excessively high, which could disrupt populations of beneficial bacteria.

According to Genetic Engineering & Biotechnology News, the researchers believe that therapies designed to restore balanced intelectin-2 levels could meaningfully benefit IBD patients, potentially reducing inflammation and reinforcing gut integrity without the side effects associated with current immunosuppressive treatments.

Antibiotic-Resistant Pathogens in the Crosshairs

Beyond IBD, the findings open a parallel avenue: leveraging intelectin-2 as a novel antimicrobial agent. As antibiotic resistance grows into one of the most urgent global health threats, proteins that can neutralize resistant strains like MRSA represent a compelling alternative to conventional drugs. Because intelectin-2 targets microbial sugars rather than proteins, bacteria may have fewer evolutionary pathways to develop resistance against it.

As reported by MIT News, the research team is now exploring whether intelectin-2 or engineered variants of it could be developed into therapeutic agents.

A Broader Wave of Gut Immunity Research

The intelectin-2 study is part of a wider surge in biomedical discoveries redefining mucosal immunity. Separately, researchers have identified GATA6 as a molecular switch governing whether pancreatic cancer cells respond to chemotherapy — a finding that, like the intelectin-2 work, highlights how fundamental biology can unlock new clinical strategies. Together, these March 2026 discoveries signal a productive period for translational medicine.

For the millions suffering from chronic gut inflammation, intelectin-2 represents a promising target — one that works with the body's own defenses rather than overriding them.